David Reitman coauthored a chapter on estimating merger effects entitled “Research Topics in Unilateral Effects Analysis” in Research Handbook on the Economics of Antitrust Law. For more information, click here.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...
